Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Global X NASDAQ 100 Covered Call ETF trades at $18.64 (market cap $8.54B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 8.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| MRVI | QYLD | |
|---|---|---|
Market Cap | $972.90M | $8.54B |
Volume | 4,325,710 | 2,383,712 |
Sector | Health | Income / Options Overlay |
52-Week High | $9.00 | $18.69 |
52-Week Low | $2.83 | $16.70 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF's technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels above 75 indicating overbought conditions. Recent news highlights its high monthly dividend yield but raises concerns about long-term capital erosion and capped upside due to its covered call strategy, with distributions consistently at $0.18 per share.
The outlook for QYLD is mixed; it offers attractive income with a high yield, appealing for investors seeking monthly cash flow. However, risks include limited growth potential, declining option premiums, and potential tax reclassification of dividends. Analyst sentiment is divided, with some upgrades citing yield attractiveness but others warning of principal erosion over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
